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Erhan Guler a, Unsal Vural aaDr Siyami Ersek Educational and Research Hospital of Cardiovascular and Thoracic Surgery, Istanbul
a TurkeyIntroduction: Oral anticoagulation with warfarin is indicated for patients with prosthetic heart valves. The effects of
religious fasting during Ramadan month (in the Islamic calendar) on anticoagulation aren’t clear.
Objectives: To study the impact of Ramadan fasting on international normalized ratio (INR), quality of anticoag-
ulation, dose of warfarin used and blood osmolarity.
Methods: 18 patients were followed-up prospectively for 3 months (pre- Ramadan, Ramadan and post-Ramadan
months). Patients presented for weekly visits in which blood samples were obtained.
Results: No significant difference in INR and warfarin dose was found between Ramadan month, and months
before and after it. The post-Ramadan INR was significantly larger than pre-Ramadan (p = 0.004). Blood osmolarity
was significantly lower during Ramadan compared to pre- and post-Ramadan months. A significantly better quality
of anticoagulation was noticed during Ramadan (p < 0.001). A significantly larger ratio of supratherapeutic INR val-
ues occurred in the post-Ramadan month (p < 0.05). A significantly larger ratio of infra-therapeutic INR values was
noticed in the pre-Ramadan month (p < 0.05).
Conclusion: No significant difference in mean INR or warfarin dose was found and a better quality of anti-
coagulation was achieved during Ramadan. A tendency toward supra-therapeutic anticoagulation occurred after
Ramadan, thus a closer follow up during this period may be reasonable.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patients with prosthetic heart valves (PHVs)require chronic oral anticoagulation.
Although newer oral antithrombotic agents(rivaroxaban, apixaban, dabigatran, etc.) are now
available, current guidelines do not recommend
their use for antithrombotic therapy in patients
with PHVs [1–3]. Vitamin K antagonists (mainly
warfarin) remain the most widely used agents
for this purpose.eCCBY-
Abbreviations
PHV prosthetic heart valve
INR international normalized ratio
AST aspartate aminotransferase
ALT alanine aminotransferase
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2017;29:1–6During the 9th month of the Islamic calendar,
the month of Ramadan, Muslims fast from sunrise
to sunset. Since it is emphasized that patients’ diet
may affect the efficacy of anticoagulation, clini-
cians are frequently faced with the question
whether a patient taking warfarin can fast or not.GGT gamma-glutamyl transferase
ALP alkaline phosphatase
BUN blood urea nitrogen
AVR aortic valve replacement
MVR mitral valve replacement
BMI body mass indexMaterials and methods
The study was conducted between May 22, 2015
and August 14, 2015. The study was approved by
the Ethics Committee of the Dr Siyami Ersek
Cardiovascular and Thoracic Surgery Educational
and Research Hospital, Istanbul, Turkey.
The hospital records were screened for adult
patients living in Istanbul and taking warfarin
who underwent mitral, aortic, or tricuspid valve
replacement surgery between April 2014 and
March 2015. 243 patients were contacted by phone
and given brief information about the study. The
patients were invited for an initial assessment visit
in which they were provided with further details
of the study, their demographic information was
recorded and they underwent a medical assess-
ment to ensure they were fit to fast.
A schedule of 12 weekly follow-up visits was
prepared. Four visits were in the pre-Ramadan
month, four during Ramadan, and four in the
post-Ramadan month. In each visit, blood sam-
ples were obtained to measure international nor-
malized ratio (INR) and the total amount of
warfarin used in the previous week was recorded.
Biochemical markers for hepatic dysfunction
(alkaline phosphatase, alanine aminotransferase,
aspartate aminotransferase, c-glutamyl trans-
ferase, total protein, and albumin) were also
obtained. Sodium, potassium, blood urea nitrogen
(BUN), and glucose levels were obtained and used
to calculate blood osmolarity using the equation:
2 ðNaþ KÞ þ ðGlucose=18Þ þ ðBUN=2:8Þ: ð1Þ
Signs and symptoms of major bleeding and
thrombotic events were questioned in each visit.
The therapeutic INR range used in our study
was 2.0–3.50. The warfarin dose was adjusted
when the INR values were out of this range.
Patients were asked to take warfarin when they
woke up for the meal of suhur (the meal just
before sunrise). No adjustment of the other med-
ications was made and no specific instructions
about when to take them was made. Patients con-
tinued to take diuretics during Ramadan in their
usual doses. Enoxaparin was prescribed for 5 days
when subtherapeutic INR values were obtained.
The primary outcome of this study is the mean
INR value before, during, and after Ramadan.Secondary outcomes are the dose of warfarin
used, quality of anticoagulation, blood osmolarity,
and any biochemical evidence of hepatic dysfunc-
tion that may cause variation in the INR before,
during, and after Ramadan. Clinical endpoints
for termination of the study included any major
hemorrhagic or thrombotic events.
Descriptive statistics were used to report
patients’ demographic data. Data are expressed
as mean ± standard deviation for continuous vari-
ables and percentages for categorical variables.
Paired sample t test was used to compare the vari-
ables in the three study periods (pre-Ramadan,
Ramadan, and post-Ramadan). A p value <0.05
was considered statistically significant. All statisti-
cal analyses were performed using SPSS version
22.0 (IBM-SPSS Inc., Armonk, NY, USA).Results
Thirty-six patients presented for the initial visit.
Two patients were considered medically unfit to
fast and they were excluded from the study (these
patients were both frail, elderly, diabetic, and on
multiple medications). Nine patients did not con-
sent to the study protocol. Three patients could
not tolerate fasting this year so they were
excluded on the first follow-up visit in Ramadan.
Four patients were lost to follow up (these 4
patients went to their hometowns to celebrate
the feast after Ramadan and they then spent the
summer vacation there). Eighteen patients met
the minimum criteria for inclusion in the study,
which were as follows: patients who presented
for follow up at least twice before and during
Ramadan and at least once after Ramadan. Details
of our patient recruitment process are illustrated
in Fig. 1.
The study cohort included 12 (66.7%) men and
six women. The mean age was 52.7 ± 13.2 years.
Twelve participants had mitral valve replacement
and six participants had aortic valve replacement;
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Figure 1. Consort study algorithm.
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EFFECTS OF RAMADAN FASTING ON ANTICOAGULATIONthere were no cases of both valves being replaced.
Five patients had normal body mass index, eight
patients were overweight, and five patients were
obese. The mean body mass index was
28.47 ± 4.89 kg/m2. No major hemorrhagic or
thrombotic event was recorded. The demographic
data of the study population are summarized in
Table 1.
The mean values of the blood tests were calcu-
lated for the three study periods as shown in
Table 2. The mean INR in the post-RamadanTable 1. Patient demographics.
Study population (n = 18)
Median age, y 52.7 ± 13.2
Age groups (y)
645 5 (27.8)
45–60 9 (50.0)
P60 4 (22.2)
Sex
Male 12 (66.7)
Female 6 (33.3)
Surgery
MVR 12 (66.7)
AVR 6 (33.3)
Mean BMI, kg/m2 28.47 ± 4.89
BMI groups
20–25 kg/m2 (Normal) 5 (27.8)
25–30 kg/m2 (Overweight) 8 (44.4)
P30 kg/m2 (Obese) 5 (27.8)
Data are presented as n (%) or mean ± standard deviation.
AVR = aortic valve replacement; BMI = body mass index; MVR = mitral
valve replacement.month was insignificantly higher compared to
Ramadan (p = 0.059). The mean INR was signifi-
cantly higher in post-Ramadan compared to pre-
Ramadan (2.47 ± 0.57 vs. 3.05 ± 0.69, respectively;
p = 0.004). No statistical difference in the mean
warfarin dose taken was found. Biochemical
markers of hepatic dysfunction did not show a sig-
nificant difference between the three study peri-
ods. Surprisingly, the mean osmolarity was
significantly lower during Ramadan compared to
the pre- and post-Ramadan periods (p = 0.048
and p = 0.038, respectively).
Fluctuation in the quality of anticoagulation
throughout the study is illustrated in Fig. 2 and
Table 3. The highest ratios of therapeutic anticoag-
ulation were recorded in the last 2 weeks of Rama-
dan (88.89% and 87.5%). The lowest ratio of
therapeutic anticoagulation was noticed in the 1st
week after Ramadan (60.0%). Seventy percent of
INR values obtained in the pre-Ramadan month
were within the therapeutic range, 82.1% in Rama-
dan, 75.5% in the post-Ramadan month and the
overall ratio throughout the 3-month study period
was 76.1%. No significant difference was found
between the pre- and post-Ramadan months
(p = 0.159). However, a significantly higher ratio
of therapeutic INR was found during Ramadan
compared to the pre- and post-Ramadan months
(both p < 0.001). Of the INR values obtained dur-
ing the post-Ramadan period, 18.9% were
supratherapeutic, compared to 6.7% in the pre-
Ramadan and 4.5% in the Ramadan period
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Table 2. Results of blood tests expressed as the mean values of the tests in each of the study periods (mean ± standard deviation).
Pre-Ramadan Ramadan Post-Ramadan p
Pre-Ramadan
vs. Ramadan
Ramadan vs.
post-Ramadan
Pre-Ramadan vs.
post-Ramadan
Mean INR 2.47 ± 0.57 2.67 ± 0.37 3.05 ± 0.69 0.183 0.059 0.004*
Mean weekly warfarin
dose (mg)
36.68 ± 12.25 37.78 ± 12.81 36.56 ± 14.11 0.516 0.305 0.959
Mean calculated osmolarity
(mosm/kg)
299.5 ± 3.94 297.9 ± 3.98 298.6 ± 3.85 0.048* 0.460 0.038*
Mean ALP (U/L) 88.57 ± 23.51 89.31 ± 32.49 86.69 ± 18.86 0.844 0.376 0.156
Mean potassium (mEq/L) 4.42 ± 0.42 4.53 ± 0.40 4.37 ± 0.44 0.103 0.033* 0.530
Mean sodium (mEq/L) 139.67 ± 1.40 138.59 ± 1.80 139.47 ± 1.21 0.010* 0.198 0.092
Mean albumin (g/dL) 4.35 ± 0.25 4.43 ± 0.29 4.30 ± 0.29 0.009* 0.027* 0.610
Mean total protein (g/dL) 7.68 ± 0.34 7.76 ± 0.41 7.59 ± 0.46 0.069 0.050 0.344
Mean GGT (U/L) 33.28 ± 23.55 31.85 ± 23.46 30.65 ± 22.09 0.409 0.055 0.518
Mean AST (U/L) 21.84 ± 4.26 21.67 ± 4.22 23.11 ± 6.64 0.816 0.275 0.122
Mean ALT (U/L) 18.09 ± 5.99 18.56 ± 8.54 18.39 ± 8.49 0.792 0.210 0.819
Mean BUN (mg/dL) 16.22 ± 3.47 17.46 ± 4.79 15.54 ± 3.17 0.219 0.104 0.281
Mean glucose (mg/dL) 101.34 ± 23.64 101.19 ± 18.10 97.77 ± 26.62 0.963 0.127 0.153
Data are presented as mean ± standard deviation.
ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; GGT = c-glutamyl
transferase; INR = international normalized ratio.
* p < 0.05.
Figure 2. Fluctuation in quality of anticoagulation throughout the study weeks.
Table 3. Percentage of international normalized ratio (INR) values according to the therapeutic range across the study periods.
Pre-Ramadan Ramadan Post-Ramadan p
Pre-Ramadan vs.
Ramadan
Ramadan vs.
post-Ramadan
Pre-Ramadan vs.
post-Ramadan
Supra-therapeutic INR 6.7 (4) 4.5 (3) 18.9 (10) 0.709 0.001* 0.013*
Therapeutic INR 70 (42) 82.1 (55) 75.5 (40) <0.001* <0.001* 0.159
Infra-therapeutic INR 23.3 (14) 13.4 (9) 5.7 (3) <0.001* 0.083 0.044*
Data are presented as % (n).
* p < 0.05.
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EFFECTS OF RAMADAN FASTING ON ANTICOAGULATION(p = 0.013 and p = 0.001, respectively). Of the INR
values obtained during the pre-Ramadan period,
23.3% were infratherapeutic, compared to 5.7%
post-Ramadan and 13.4% in the Ramadan period
(p = 0.044 and p < 0.001; respectively). The largest
difference in anticoagulation quality between 2
consecutive weeks was noticed between the last
week of Ramadan and the 1st week of post-
Ramadan month (87.5% vs. 60.0%).
Discussion
In our study, the mean INR was significantly
higher after Ramadan compared to the pre-
Ramadan month (3.05 vs. 2.47, p = 0.004). INR
was also insignificantly higher during Ramadan
compared to pre-Ramadan (2.47 vs. 2.67,
p = 0.183). Lai et al. [8] reported a statistically sig-
nificant increase in INR in Ramadan compared
to the months preceding and following months,
which they attributed to dietary factors, changes
in sleep patterns, and alterations in time of food
and drug intake. By contrast, our study noticed a
progressive increase in INR throughout the dura-
tion of the study. No difference in warfarin dose
taken was found between the three study periods,
which suggests that this increase in INR may be
related to the factors suggested by Lai et al. [8].
In addition, it may be reasonable to consider dif-
ferences of climate and seasonal foods as possible
factors that may cause the difference between our
results and those of Lai et al. [8].
Biochemical markers of hepatic dysfunction did
not show any significant difference throughout
the study period, which eliminates this factor as a
possible reason behind the changes observed in
INR levels. This is consistentwith the data reported
by Chamsi-Pasha et al. [6] who did not identify any
evidence of liver dysfunction during Ramadan.
Due to the lack of evidence in this topic, some of
our colleagues have hypothesized that fasting may
lead to dehydration, and thus increase blood vis-
cosity, which may predispose the patients to
thrombotic events. In this study, we calculated
the blood osmolarity after 9–11 hours of fasting
using the equation:
2 ðNaþ KÞ þ ðGlucose=18Þ þ ðBUN=2:8Þ: ð2Þ
No significant difference in blood glucose and
BUN levels was found. This contradicts the results
of other metabolic studies which reported a
decrease in glucose levels, high density lipopro-
tein, and body weight during Ramadan, along
with an increase in low density lipoprotein [9,10].
This may be attributed to the fact that blood sam-
ples in these studies were obtained at least12 hours after the last meal [9], whereas blood
samples in our study were obtained earlier (about
9–11 hours after the last meal). By contrast, studies
conducted by Rashed et al. [11] and Fedail et al.
[12] reported a mild increase or a mild variation
in blood glucose levels in Ramadan which sup-
ports the data presented in the current study.
Mean sodium level was significantly higher dur-
ing the pre-Ramadan month compared to Rama-
dan (139.67 mEq/L vs. 138.59 mEq/L; p = 0.010).
Mean potassium level was significantly higher
during Ramadan compared to the post-Ramadan
month (4.53 mEq/L vs. 4.37 mEq/L; p = 0.033). Sur-
prisingly, a significantly lower mean calculated
blood osmolarity was found during the month of
Ramadan compared to the pre- and post-
Ramadan periods (p < 0.05). Therefore, we could
not demonstrate any evidence of increased osmo-
larity that may lead to increased blood viscosity
predisposing to thrombotic events. Moreover, no
thrombotic (or hemorrhagic) events were docu-
mented throughout the study period.
In contrast to the results of Lai et al. [8], in our
study, the best quality of anticoagulation was
achieved during Ramadan, with 82.1% of the INR
values obtained falling within the therapeutic
range. Of the INR values obtained in the pre-
Ramadanmonth, 23.3%were infratherapeutic; this
ratio was noticed to decrease progressively over
the study periods despite no significant change
in the total amount of warfarin taken. A steep
increase in the proportion of supratherapeutic
INR values was noticed between Ramadan and
the post-Ramadan months (4.5% and 18.9%;
p = 0.001). This was reflected in a significant
increase in the mean INR value between these
months (from 2.67 to 3.05; p = 0.004). Again, these
findings contradict those of Lai et al. [8], who
reported a significant decrease inmean INR values
between Ramadan and the post-Ramadan periods.
In addition, Lai et al. [8] noticed a significant
increase in time below therapeutic range in the
post-Ramadan month. Therefore, we could not
reproduce the results of the above mentioned
study and we obtained a contradictory set of data.
The largest weekly fluctuation in the ratio of
patients with optimal therapeutic anticoagulation
was noticed between the last week of Ramadan
and the 1st week of post-Ramadan period (87.5%
vs. 60.0%). A similar observation was also noticed
in Lai et al.’s study [8]. This difference is probably
caused by the significant changes in dietary habits
after Ramadan and the feast celebrated during the
1st week after Ramadan. Since the period of time
within the therapeutic range significantly impact
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clinicians to emphasize the importance of a close
INR follow up during this period.
Limitations of this study include the low num-
ber of participants and enrolling patients in the
follow-up program without ensuring that they
had stable INR levels prior to enrolment. This
might have affected the INR values especially in
the first weeks of follow up. We intentionally
chose to include all patients regardless of their
previous anticoagulation profile so as to imitate
the general population of patients taking warfarin
for PHVs. Also, the study did not examine the INR
levels of non-fasting patients. Comparison of the
results of this study with this group of nonfasting
patients might help to clarify further the effects of
fasting on anticoagulation therapy. The small
number of patients included decreases the power
of this study and thus studies including larger
numbers of patients need to be conducted to clar-
ify further the effects of Ramadan fasting on the
quality of anticoagulation with warfarin.Conclusion
Although the best quality of anticoagulation was
observed during Ramadan, a dramatic decrease in
the therapeutic INR ratio occurred in the 1st week
of the following month. Thus, clinicians should
emphasize the importance of intensive INR follow
up during this period.
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